Biotin

Biotin operates as the covalently-attached prosthetic group for five carboxylase enzymes, bound to a specific lysine residue on the enzyme via an amide bond formed by holocarboxylase synthetase (HCS). This covalent attachment is unusual among vitamin cofactors (most flavins, nicotinamides, and pyridoxals are non-covalent), and it means that biotin stays with "its" enzyme through the catalytic cycle, shuttling between a carboxylase domain where it is activated and a carboxyltransferase domain where it transfers CO2 to the substrate.

The carboxylase reaction mechanism. All biotin-dependent carboxylases use a common chemistry: (1) ATP-dependent carboxylation of the N1′ nitrogen of the biotin ureido ring with bicarbonate to form carboxybiotin (releasing ADP + Pi), (2) translocation of carboxybiotin to the carboxyltransferase active site, (3) transfer of CO2 from carboxybiotin to the substrate, and (4) regeneration of free biotin to begin a new cycle. This two-step, two-site chemistry allows biotin carboxylases to overcome the thermodynamic barrier of direct carboxylation at physiologic bicarbonate concentrations.

The five biotin-dependent human carboxylases. (1) Pyruvate carboxylase (PC) is mitochondrial and catalyzes the carboxylation of pyruvate to oxaloacetate. This is the anaplerotic replenishment of TCA cycle intermediates and the first committed step of gluconeogenesis from pyruvate/lactate/alanine. Under fasting conditions or high protein intake, PC activity is essential for maintaining blood glucose via gluconeogenesis. Pyruvate carboxylase deficiency is a severe genetic disorder with neonatal lactic acidosis and profound neurological impairment. (2) Acetyl-CoA carboxylase 1 (ACC1, ACACA) is cytosolic and catalyzes the carboxylation of acetyl-CoA to malonyl-CoA — the rate-limiting and highly regulated first committed step of fatty acid synthesis. ACC1 is heavily regulated by phosphorylation (AMPK phosphorylation inactivates ACC1, coupling energy status to lipogenesis; insulin signaling dephosphorylates and activates ACC1), allosteric activation by citrate, and transcriptional regulation by SREBP-1. (3) Acetyl-CoA carboxylase 2 (ACC2, ACACB) is mitochondrial outer membrane-bound and produces malonyl-CoA at the mitochondrial surface, where it inhibits carnitine palmitoyltransferase 1 (CPT1) and thereby regulates fatty acid entry into mitochondria for β-oxidation. ACC1 and ACC2 thus perform complementary malonyl-CoA generation for distinct regulatory purposes — cytosolic for synthesis, mitochondrial for oxidation gating. (4) Propionyl-CoA carboxylase (PCC) is mitochondrial and catalyzes the carboxylation of propionyl-CoA to methylmalonyl-CoA, the first step in the catabolism of odd-chain fatty acids, branched-chain amino acids (valine, isoleucine, threonine, methionine via the methionine salvage pathway), and cholesterol side chain. PCC deficiency is propionic acidemia, a severe neonatal metabolic disease. (5) 3-Methylcrotonyl-CoA carboxylase (MCC, methylcrotonyl-CoA carboxylase) is mitochondrial and catalyzes a step in the catabolism of leucine. MCC deficiency produces 3-methylcrotonylglycinuria, which varies widely in clinical severity.

Multicarboxylase deficiency. Loss of biotinidase or holocarboxylase synthetase function produces a combined deficit of all five carboxylases simultaneously — the "multicarboxylase deficiency" phenotype of profound metabolic acidosis, lactic acidosis (PC deficit), hyperammonemia (PCC/MCC deficit impairing protein handling), characteristic organic aciduria (methylcrotonylglycine, 3-hydroxyisovalerate, methylcitrate, propionic acid), dermatitis, alopecia, neurological impairment (ataxia, seizures, developmental delay), conjunctivitis, and sensorineural hearing loss or optic atrophy when treatment is delayed. The dramatic response to pharmacologic biotin in these disorders (biotinidase deficiency responds to 5-10 mg/day oral biotin with normalization of carboxylase activity within days) shows the cofactor role.

Biotinidase and biotin recycling. Once a carboxylase is degraded (normal protein turnover), the biotin is released as biocytin (biotin covalently bound to a lysine residue of the digested enzyme). Biotinidase (BTD) is a plasma and lysosomal enzyme that hydrolyzes biocytin to liberate free biotin, allowing recycling. Biotinidase deficiency disrupts this recycling loop, producing functional biotin deficiency despite adequate dietary intake — hence the dramatic response to pharmacologic oral biotin, which can supply the obligate one-time use of newly synthesized carboxylases without requiring recycling. Biotinidase deficiency is classified as profound (<10% of normal activity, the form detected by newborn screening and treated with 5-10 mg/day) or partial (10-30% activity, often asymptomatic, may be treated with 1-5 mg/day prophylactically). Biotinidase also acts on dietary protein-bound biotin (biotin covalently bound to food proteins), releasing free biotin for absorption.

Biotin absorption and transport. Dietary biotin exists as free biotin and as protein-bound biotin (covalently attached to food proteins). Intestinal proteases release biocytin from food proteins, and then biotinidase further hydrolyzes biocytin to free biotin. Free biotin is absorbed across the enterocyte apical membrane predominantly by sodium-dependent multivitamin transporter (SMVT, SLC5A6), a saturable transporter shared with pantothenic acid and α-lipoic acid. At physiologic intakes, absorption is efficient; at pharmacologic oral doses, passive diffusion contributes increasingly. Colonic bacteria synthesize substantial biotin, a portion of which is absorbed by colonic SMVT expression — contributing meaningfully to biotin supply especially in the absence of high dietary intake. This colonic bacterial contribution is why frank dietary biotin deficiency is rare even with biotin-poor diets. Cellular uptake of biotin across peripheral tissue membranes uses SMVT and the monocarboxylate transporter 1 (MCT1). Renal reabsorption preserves biotin against urinary loss.

Biotin-anticonvulsant interaction. Phenytoin, carbamazepine, phenobarbital, and primidone reduce plasma biotin through a combination of accelerated catabolism (hydroxylation of the biotin valeric acid side chain), impaired absorption, and possibly impaired protein binding. Chronic anticonvulsant use over years can produce measurably reduced biotin status and occasionally symptomatic deficiency. The clinical implication is routine biotin supplementation (100-300 μg/day or a multivitamin) in long-term anticonvulsant therapy; isolated biotin deficiency symptoms are rare but the prophylaxis is low-cost and reasonable.

Raw egg white avidin biology. The classical "egg-white injury" syndrome arose from prolonged consumption of raw egg whites in diets (bodybuilders, cases reported in sailors subsisting on raw eggs). The egg-white glycoprotein avidin binds biotin with K_d ≈ 10^-15 M — among the strongest non-covalent biological interactions known — and the avidin-biotin complex is not dissociable under physiologic conditions, preventing intestinal absorption. Cooking denatures avidin and renders it non-functional. Raw egg yolks do not contain functional avidin; the issue is specifically raw egg whites. The avidin-biotin system has been exploited in laboratory technology (ELISA, immunohistochemistry, drug targeting) for the specificity of avidin-biotin binding — which is also the source of the clinically important biotin-immunoassay interference discussed below.

Biotin and laboratory assay interference. Modern clinical laboratory immunoassays (troponin, TSH, T3, T4, thyroglobulin, hCG, vitamin D, sex hormones, PSA, cortisol, parathyroid hormone, many others) frequently use streptavidin-biotin capture chemistry for signal generation. At normal plasma biotin concentrations (typically 200-2000 pg/mL with routine diet), assay interference is negligible. At pharmacologic doses (5-10 mg biotin daily for biotinidase deficiency, 10-30 mg/day for "high-dose" hair/nails supplements, 100-300 mg/day for the former MS MD1003 protocol), plasma biotin concentrations can reach 1000+ ng/mL — thousands of times higher than physiologic — and biotin competes with streptavidin-biotin assay chemistry to produce falsely high or falsely low results depending on the assay format (competitive vs sandwich assays). The FDA 2017 safety communication and subsequent updates warn that this interference can produce false troponin results that delay MI diagnosis, false TSH results that misdirect thyroid management, and false hCG results with obvious pregnancy-diagnostic consequences. Mitigation: stop biotin supplementation 24-72 hours before relevant labs (longer for very high-dose use), inform laboratory and clinician of biotin use, and if interference is suspected, use biotin-free assay platforms or sample pretreatment protocols that some laboratories offer.

Biotin (vitamin B7, also called vitamin H from the German Haut for "skin" and historically named coenzyme R, factor W, factor R, factor X, vitamin Bw, or Bios II in various discovery-era nomenclatures) is a water-soluble vitamin that serves as the covalently-attached prosthetic group for five carboxylase enzymes in human metabolism: pyruvate carboxylase, acetyl-CoA carboxylase 1, acetyl-CoA carboxylase 2, propionyl-CoA carboxylase, and 3-methylcrotonyl-CoA carboxylase. These enzymes sit at central nodes of gluconeogenesis, fatty acid synthesis, fatty acid oxidation, amino acid catabolism, and odd-chain fatty acid metabolism — so biotin has a quiet but essential metabolic role despite its obscurity in popular nutrition discourse (which emphasizes biotin primarily as a hair/skin/nails supplement, an indication with remarkably thin evidence base). The adult adequate intake is 30 μg/day for men and women, 30 μg/day in pregnancy, 35 μg/day in lactation — expressed as AI rather than RDA because epidemiological intake data are insufficient to derive a full RDA. There is no established tolerable upper intake level because biotin has an exceptionally wide therapeutic window; pharmacologic doses of 5-20 mg/day are used for biotinidase deficiency without toxicity, and doses up to 300 mg/day were used in the failed MS MD1003 trial without dose-limiting adverse effects other than the well-documented laboratory assay interference. Primary biotin deficiency from inadequate dietary intake is extraordinarily rare because (a) colonic bacteria synthesize substantial quantities of biotin that are partially absorbed by the host, (b) dietary biotin is widely distributed in eggs, dairy, meat, fish, nuts, seeds, whole grains, and vegetables, and (c) the metabolic turnover of biotin is slow. When biotin deficiency does occur, it arises from specific circumstances: raw egg white consumption (the classical "egg-white injury" syndrome of the 1920s-1940s, in which the glycoprotein avidin in raw egg whites binds biotin with an affinity ~10^15 M^-1 — one of the strongest non-covalent interactions in biology — blocking intestinal absorption; cooking denatures avidin and eliminates the problem), long-term anticonvulsant therapy (phenytoin, carbamazepine, phenobarbital, primidone increase biotin catabolism and impair biotin-enzyme complex formation), chronic hemodialysis, total parenteral nutrition without biotin supplementation, hyperemesis gravidarum, isotretinoin (modest effect), and chronic alcoholism. Symptomatic biotin deficiency produces a distinctive clinical picture of alopecia (progressive hair loss including eyebrows and body hair), perioral and periorificial scaly erythematous dermatitis (involving the nose, mouth, eyes, and perineum), glossitis with red inflamed tongue, conjunctivitis, ataxia, seizures, and lactic acidosis in severe cases — the picture of combined carboxylase deficiency from functional biotin insufficiency. Two monogenic disorders of biotin metabolism produce neonatal/early-childhood presentations that respond dramatically to pharmacologic biotin: biotinidase deficiency (BTD, 1 in 60,000 births, included in universal newborn screening in most US states since 2006; treated lifelong with oral biotin 5-10 mg/day, with excellent clinical outcomes if diagnosed pre-symptomatically) and holocarboxylase synthetase deficiency (HCS deficiency, rarer, presenting in the neonatal period with severe lactic acidosis and multicarboxylase deficiency; treated with higher-dose biotin 10-80 mg/day, with variable response that is generally better for early-onset/severe mutations). The supplement and clinical uses of biotin cluster in several domains. Biotinidase deficiency treatment is the highest-evidence indication — lifelong oral biotin 5-10 mg/day produces complete resolution of the multicarboxylase deficiency phenotype and excellent long-term neurodevelopmental outcomes, with rare residual features (sensorineural deafness, optic atrophy) in patients treated late. Holocarboxylase synthetase deficiency requires higher biotin doses and response varies by genotype. Hair, skin, and nails is the most commercially important but evidence-weakest indication: despite enormous consumer demand and aggressive marketing of high-dose biotin (2,500-10,000 μg/day, sometimes up to 30,000 μg/day) for hair loss, nail brittleness, and cosmetic skin concerns, the 2017 complete review by Patel (PMID 28879195) found the evidence base limited to a small number of case reports and open-label studies with quality issues; placebo-controlled trials in healthy individuals with uncomplicated hair/nail complaints are essentially absent. The evidence that does exist is for biotin in diagnosed biotin deficiency, in specific conditions like brittle nail syndrome (where 2.5 mg/day may help based on limited data), and in uncombable hair syndrome (Colombo 1990). Most marketed high-dose biotin for cosmetic use is a placebo effect overlaying the normal course of hair and nail growth. Progressive multiple sclerosis was the target of the high-dose MD1003 biotin (300 mg/day) program developed by MedDay Pharmaceuticals; the MS-SPI trial (Tourbah 2016, PMID 27589059) showed modest benefit in primary and secondary progressive MS, generating substantial enthusiasm, but the larger SPI2 trial completed in 2020 failed to replicate the benefit, and the MD1003 program was subsequently discontinued. High-dose biotin is not currently recommended for progressive MS. Biotin-thiamine-responsive basal ganglia disease treatment combines biotin and thiamine at pharmacologic doses (see the Thiamine entry for this SLC19A3 genetic disorder). Laboratory assay interference is a critical safety concern distinct from direct biotin toxicity: the FDA issued a safety communication in 2017 warning that high-dose biotin supplementation can produce falsely elevated or falsely low results on streptavidin-biotin-based immunoassays used for troponin, TSH, hCG, vitamin D, sex hormones, thyroid panels, and cardiac markers — a genuinely important clinical concern in emergency medicine where false troponin readings can delay MI diagnosis. Patients should discontinue biotin supplementation for at least 24-72 hours (and sometimes up to a week) before relevant laboratory testing, and should always disclose biotin use to clinicians ordering labs. Food sources of biotin concentrate in egg yolks (cooked eggs; raw egg whites are problematic because of avidin), beef liver (1 ounce provides ~50% of adult AI), salmon, pork, chicken, yeast (nutritional yeast and Brewer''s yeast), nuts and seeds (almonds, sunflower seeds, peanuts), sweet potatoes, avocado, cauliflower, spinach, and mushrooms. See also Thiamine for the biotin-thiamine-responsive basal ganglia disease partnership, Niacin for the B-complex context, Vitamin B6, Folate, Vitamin B12, Riboflavin, and Choline for the broader B-complex network, Alpha-Lipoic Acid for the parallel cofactor role in PDH/αKGDH (lipoic acid is structurally reminiscent of biotin as a carboxylic-acid-terminating heterocyclic ring system — though biochemically distinct), and CoQ10 for the shared mitochondrial bioenergetic context. This overview is educational only and is not medical advice — the clinically important practical caution is laboratory assay interference, not direct toxicity.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Biotin Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Sign in to set alerts

Related Compounds

View All

Related Articles

All Posts

Data Completeness

50%